Who is sponsoring NCT03447223?

NCT03447223 is sponsored by Xijing Hospital.

What condition does NCT03447223 study?

NCT03447223 studies Attention-deficit/Hyperactivity Disorder.

Is NCT03447223 still recruiting?

NCT03447223 is currently completed. Last updated 27 August 2021.

Last reviewed 2021-08-27 · How we verify

NCT03447223: ADHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gut Microbiome and Serum Metabolome Alterations in ADHD Patients

Completed Last updated 27 August 2021

What this trial tests

trial in Attention-deficit/Hyperactivity Disorder in 207 participants. Completed in 27 May 2020.

Timeline

20 March 2018

Primary endpoint
27 February 2020

27 May 2020

Quick facts

Lead sponsor	Xijing Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	207
Start date	20 March 2018
Primary completion	27 February 2020
Estimated completion	27 May 2020
Sites	1 location across China

Conditions studied

Attention-deficit/Hyperactivity Disorder — all drugs for Attention-deficit/Hyperactivity Disorder →

Sponsor

Xijing Hospital

Who can join

Adults 6 to 15, any sex, with Attention-deficit/Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Host-microbe interactions play a key role in brain development and function and in the etiology of neurodevelopmental disorders. Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous disorder that affects 1 in 20 children and results in poor life-time outcomes. However, the etiology of ADHD is unclear and its diagnosis and treatment are still challenging. Different factors reported to be associated with the risk of developing ADHD and/or linked to different ADHD manifestations have also been linked to shifts in gut microbiota composition, suggesting a link between the microbiota and the disorder. Here, we will perform a metagenome-wide association study and serum metabolomics profiling in a cohort of control and ADHD, 6-15 years, Chinese individuals. We aim to identify ADHD-associated gut microbial species linked to changes in circulating metabolites. We also aim to find the possible intervention strategy in ADHD by targeting the gut microbiota.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Gut metagenomic characteristics of ADHD reveal low <i>Bacteroides ovatus</i>-associated host cognitive impairment.
Li Y, Sun H, Huang Y, Yin A, et al · · 2022 · cited 28× · PMID 36128620 · DOI 10.1080/19490976.2022.2125747
Integrative multi-omics reveals microbial genomic variants driving altered host-microbe interactions in autism spectrum disorder.
Chen W, Wang X, Zhu R, Gao W, et al · · 2026 · PMID 41421350 · DOI 10.1016/j.xcrm.2025.102516
Gut metagenomics discriminates unique microbial signatures in diverse symptomatic profiles with attention-deficit/hyperactivity disorder
Li Y, Sun H, Huang Y, Yin A, et al · · 2020 · DOI 10.21203/rs.3.rs-28862/v1

Verify or expand the search:

Other recruiting trials for Attention-deficit/Hyperactivity Disorder

Currently open trials in the same condition.

NCT06743425 — A Pilot Study of a Remote ADHD Monitoring Program · NA · recruiting
NCT06376331 — Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder · Phase 1 · recruiting

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03447223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 27 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03447223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing